GE Healthcare to Acquire Diagnostics Company Clarient
General Electric announced Friday that its healthcare unit will acquire molecular diagnostics company Clarient in a deal worth approximately $580 million.
breast cancer
Adventrx Pharmaceuticals Seeks to Improve Current Cancer Drugs
The San Diego-based company seeks to improve upon existing cancer therapeutics with its reformulations of the chemotherapy drugs Navelbine and Taxotere.
Celgene Acquires Abraxis In $2.9 Billion Deal
Celgene has acquired Abraxis BioScience in a cash-and-stock deal valued at $2.9 billion, reports FierceBiotech.
NeoMatrix: A “Pap Smear for Breast Cancer”
Neomatrix of Irvine, Calif., has developed a fully automated, non-invasive device to assess a patient’s risk of developing breast cancer.
Quantum Immunologics’ Alternative to Chemotherapy
The company’s vaccine technology is based on the universal tumor antigen, which has been expressed in all human cancers studied so far.
Defining a Radiation Target with Augmenix
The company’s SpaceOAR System is designed to temporarily separate organs during radiotherapy so that normal tissues are spared, and to mark tumor resection sites to allow for targeted therapy.
For Advaxis, Bacteria Help More Than They Hurt
The idea of using harmful bacteria to treat disease might strike many as an odd concept.
The Universal Vaccines of Inovio Biomedical
Inovio is developing a universal flu vaccine engineered to prevent several strains of influenza at once.
[OneMedForum] Clarient Grows Along with Cancer Testing Market
The Aliso Viejo, Calif.-based company achieved several major milestones in 2009.
Cytori’s (NASDAQ: CYTX) Natural Celution for Breast Reconstruction
Cytori Therapeutics is a leading global innovator in the emerging field of regenerative medicine using adipose (fat) tissue as a rich source of adult stem cells capable of differentiating into a variety of cell types.